Highly Upregulated Expression of CD36 and MSR1 in Circulating Monocytes of Patients with Acute Coronary Syndromes

• Published in: The Protein Journal 2012-08, Vol.31 (6), p.511-518
• Main Authors: Piechota, Michal, Banaszewska, Anna, Dudziak, Joanna, Slomczynski, Marek, Plewa, Robert
• Format: Article
• Language: English
• Subjects: Acute Coronary Syndrome - blood; Acute Coronary Syndrome - drug therapy; Adult; Aged; Analysis; Animal Anatomy; Animal experimentation; Anticholesteremic Agents - therapeutic use; Antilipemic agents; Atherosclerosis; Atorvastatin Calcium; Biochemistry; Bioorganic Chemistry; Blood; Blood Glucose; Cardiovascular disease; Case-Control Studies; CD36 Antigens - genetics; CD36 Antigens - metabolism; Cellular biology; Chemistry; Chemistry and Materials Science; Coronary heart disease; Coronary vessels; Development and progression; Female; Gene expression; Gene Expression - drug effects; Heptanoic Acids - therapeutic use; Histology; Humans; Lipoproteins, LDL - blood; Male; Middle Aged; Monocytes - metabolism; Morphology; Organic Chemistry; Proteins; Pyrroles - therapeutic use; Real-Time Polymerase Chain Reaction; RNA, Messenger - genetics; RNA, Messenger - metabolism; Scavenger Receptors, Class A - genetics; Scavenger Receptors, Class A - metabolism; Statistics, Nonparametric; Up-Regulation; Vein & artery diseases
• ISSN: 1572-3887; 1573-4943; 1875-8355
• DOI: 10.1007/s10930-012-9431-8

Acute Coronary Syndromes (ACS) are a group of disorders caused by the significant reduction of circulation in coronary arteries. The most common reason of the dysfunction is a blood clot formed in place of plaque rupture. The role of scavenger receptors in development and progression of atherosclerosis has been confirmed in many animal experiments, however the knowledge about contribution of the receptors in the development of ACS symptoms in humans still remains insufficient. The aim of this work was to define the expression of two scavenger receptors: CD36 and MSR1 in monocytes of patients with ACS after the onset of symptoms and after the 6 months of treatment. The analysis of CD36 and MSR1 expression was carried out with the use of real-time PCR and flow cytometry. Analyses of lipid and glucose concentration in blood and the level of inflammatory markers in plasma were performed additionally for all ACS patients. All data obtained during the research were analyzed using statistical tests, such as Mann Whitney test, Wilcoxon test, or correlation. In all patients with symptoms of ACS the amount of CD36 and MSR1 mRNA in circulating monocytes, as well as the density of both receptors on the cells surface was significantly higher. Re-analysis of subjects after 6 months of treatment, showed a significant decrease in the CD36 and MSR1 expression in all patients who received atorvastatin. The results of presented studies demonstrate that both investigated receptors are involved in the development and/or progression of ACS.